Literature DB >> 12724056

Are low target blood pressure goals justified in persons with diabetes mellitus?

Errol D Crook1, Latha Velusamy.   

Abstract

Hypertension is common in patients with diabetes and is a major risk factor for development and progression of the macro- and microvascular complications seen in diabetes. The Joint National Committee VI recommendation for goal blood pressure is less than 130/85 mm Hg in diabetics--a more aggressive target than in nondiabetic patients. Data over the past decade support these aggressive goals, especially for cardiovascular and renal outcomes and overall mortality. In addition, in diabetics, blood pressure appears to be a continuous risk factor for these outcomes without evidence of a J-point effect. While these goals are rarely obtained in diabetic patients, studies demonstrate that they are achievable with attention to detail and use of multiple antihypertensive agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724056     DOI: 10.1007/s11906-003-0026-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  37 in total

1.  Endstage renal disease owing to diabetic nephropathy in Mississippi: an examination of factors influencing renal survival in a population prone to late referral.

Authors:  E D Crook; J Harris; B Oliver; E Fleischman; G Crenshaw; R Taylor
Journal:  J Investig Med       Date:  2001-05       Impact factor: 2.895

2.  Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. A 14-year follow-up report on 195 patients.

Authors:  M Ravid; H Savin; R Lang; I Jutrin; L Shoshana; M Lishner
Journal:  Arch Intern Med       Date:  1992-06

3.  Rise in albuminuria and blood pressure in patients who progressed to diabetic nephropathy in the Diabetes Control and Complications Trial.

Authors:  William Thomas; Yingjia Shen; Mark E Molitch; Michael W Steffes
Journal:  J Am Soc Nephrol       Date:  2001-02       Impact factor: 10.121

Review 4.  Diabetes, hypertension, and cardiovascular disease: an update.

Authors:  J R Sowers; M Epstein; E D Frohlich
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

5.  Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.

Authors:  M J Garcia; P M McNamara; T Gordon; W B Kannel
Journal:  Diabetes       Date:  1974-02       Impact factor: 9.461

6.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project.

Authors:  L Niskanen; T Hedner; L Hansson; J Lanke; A Niklason
Journal:  Diabetes Care       Date:  2001-12       Impact factor: 19.112

Review 7.  Diabetic renal disease in African Americans.

Authors:  Errol D Crook
Journal:  Am J Med Sci       Date:  2002-02       Impact factor: 2.378

8.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Ocular factors in the incidence and progression of diabetic retinopathy.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Ophthalmology       Date:  1994-01       Impact factor: 12.079

10.  Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy.

Authors:  H H Parving; A R Andersen; E Hommel; U Smidt
Journal:  Hypertension       Date:  1985 Nov-Dec       Impact factor: 10.190

View more
  1 in total

Review 1.  Diabetic nephropathy in African-American patients.

Authors:  Errol D Crook; Sejal R Patel
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.